| Abdominal pain in IBS — Unique IS2 | Pain on a scale from 0 to 10 fell from 8.2 to 3.4 points with the supplement and from 8.3 to 6.7 with placebo. The between-group difference had a p-value of <0.001. | 1/4 Very lowOne study. The analysis excluded 28 of the 136 assigned participants. Different sections of the article report different pain scores. The figures here come from the week 8 findings in the Results section. This discrepancy accounts for the very low confidence in the conclusion. | 11 publication describedRandomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults ↗ | 136 adults aged 18–60 with irritable bowel syndrome (IBS) and fewer than three bowel movements per week that felt complete, without laxatives. Of the 108 participants who completed the study, 53 took the supplement and 55 took placebo. People with diarrhea-predominant IBS were excluded. | - Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults ↗
|
|---|
| Stool frequency — Unique IS2 | Stool frequency did not increase more than with placebo. The mean change was +0.05 versus +0.04 bowel movements per day (p=0.551). | 2/4 LowOne four-week study with mostly women. Stool frequency was recorded in a diary. Stool frequency changed slightly within the supplement group, without an advantage over placebo. | 11 publication describedBacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗ | Healthy adults aged 18–65 who had at least three but fewer than seven bowel movements per week that felt complete, without laxatives. The study assigned 145 participants and included 143 in the primary analysis (72 on the supplement and 71 on placebo). People with IBS or functional constipation were excluded. | - Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Stool consistency — Unique IS2 | Stool consistency improved. The score fell by 0.31 points with the supplement and rose by 0.04 points with placebo (p=0.018). The authors converted Bristol Stool Scale types to a score from 1 to 4, with lower scores indicating more favorable consistency. | 2/4 LowOne short study with mostly women. Stool consistency differed between groups at baseline. The authors accounted for baseline scores in the comparison. | 11 publication describedBacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗ | Healthy adults aged 18–65 who had at least three but fewer than seven bowel movements per week that felt complete, without laxatives. The study assigned 145 participants and included 143 in the primary analysis (72 on the supplement and 71 on placebo). People with IBS or functional constipation were excluded. | - Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Digestive quality of life — Unique IS2 | Digestive quality of life did not improve more than with placebo. The between-group difference in changes on the adapted GIQLI questionnaire was statistically nonsignificant (p>0.05). The authors did not report the size of the difference. | 2/4 LowOne four-week study involving mostly women without a diagnosed bowel disease. The authors reported no statistically significant difference between groups and provided neither the size of the difference nor its confidence interval. | 11 publication describedBacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗ | Healthy adults aged 18–65 who had at least three but fewer than seven bowel movements per week that felt complete, without laxatives. The study assigned 145 participants and included 143 in the primary analysis (72 on the supplement and 71 on placebo). People with IBS or functional constipation were excluded. | - Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Digestive symptoms — Unique IS2 | Digestive symptoms, measured using the relevant section of the GIQLI questionnaire, did not improve more than with placebo (p>0.05). The authors did not report the size of the difference. | 2/4 LowOne four-week study involving mostly women without a diagnosed bowel disease. The authors reported no statistically significant difference between groups and provided neither the size of the difference nor its confidence interval. | 11 publication describedBacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗ | Healthy adults aged 18–65 who had at least three but fewer than seven bowel movements per week that felt complete, without laxatives. The study assigned 145 participants and included 143 in the primary analysis (72 on the supplement and 71 on placebo). People with IBS or functional constipation were excluded. | - Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Bloating, belching, and gas — MTCC 5856 | The combined score for bloating, belching, and gas on a scale from 0 to 18 fell from 8.91 to 3.06 points with the supplement and from 9.42 to 8.33 with placebo. The decreases were 5.85 versus 1.09 points (p<0.001). | 2/4 LowOne small study that analyzed 66 of 70 participants. The study assessed several subjective symptoms. This result applies to bloating, belching, and gas in the group studied. | 11 publication describedThe effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study ↗ | 70 adults aged 18–65 with recurring bloating and gas. Of these, 66 completed the study, 33 in each group. People with IBS, functional constipation, lactose intolerance, or functional dyspepsia were excluded. | - The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study ↗
|
|---|
| Percentage of time asleep during overnight testing — IDCC 1201 | During overnight testing, the percentage of time asleep rose from 75.75% to 89.46% with the supplement and went from 85.08% to 84.93% with placebo, a change of +13.71 versus −0.15 percentage points. The difference persisted after adjustment for baseline values (p=0.015). | 2/4 LowOne four-week study. At baseline, the probiotic group slept worse than the placebo group. Sleep was measured objectively during overnight testing before and after supplementation. The reported change reflects those assessments and gives no estimate of the average change across nights at home. The advantage in the percentage of time asleep persisted after adjustment for baseline differences. | 11 publication describedEfficacy and Safety of Bacillus coagulans IDCC 1201 for Sleep Improvement in Adults with Sleep Disturbance: A Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study ↗ | 80 adults aged 19–65 with sleep complaints, a PSQI sleep quality score of ≥5, and an ISI insomnia score of 8–21. Of these, 78 completed the study, 39 in each group. People with severe insomnia or diagnosed sleep apnea were excluded. | - Efficacy and Safety of Bacillus coagulans IDCC 1201 for Sleep Improvement in Adults with Sleep Disturbance: A Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study ↗
|
|---|
| Sleep duration during overnight testing — IDCC 1201 | Sleep duration during overnight testing increased by an average of 49.56 minutes with the supplement and decreased by 0.50 minutes with placebo (p=0.002). At baseline, the supplement group slept an average of 272.88 minutes and the placebo group slept 306.25 minutes. | 2/4 LowOne four-week study. At baseline, the probiotic group slept worse than the placebo group. Sleep duration was an additional outcome. It was measured during overnight testing before and after supplementation. The reported change reflects those assessments and gives no estimate of the average change across nights at home. | 11 publication describedEfficacy and Safety of Bacillus coagulans IDCC 1201 for Sleep Improvement in Adults with Sleep Disturbance: A Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study ↗ | 80 adults aged 19–65 with sleep complaints, a PSQI sleep quality score of ≥5, and an ISI insomnia score of 8–21. Of these, 78 completed the study, 39 in each group. People with severe insomnia or diagnosed sleep apnea were excluded. | - Efficacy and Safety of Bacillus coagulans IDCC 1201 for Sleep Improvement in Adults with Sleep Disturbance: A Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study ↗
|
|---|
| Body weight — BC99 | Body weight fell in both groups, with no advantage for BC99 over placebo. It fell from 82.53 to 80.39 kg with BC99 and from 80.80 to 78.51 kg with placebo. The changes were −2.14 and −2.29 kg, respectively. | 2/4 LowOne small study. Body weight and blood lipid measures were additional outcomes. The conclusion applies to all participants combined. A result from one subgroup cannot be generalized to the entire sample. | 11 publication describedEffect of Bacillus coagulans BC99 supplementation on body weight and gut microbiota in overweight and obese individual: a randomized, double-blind, placebo-controlled study ↗ | 66 adults aged 18–65 with overweight or obesity in China, 33 in each group. Each group included 20 participants with overweight and 13 with obesity. | - Effect of Bacillus coagulans BC99 supplementation on body weight and gut microbiota in overweight and obese individual: a randomized, double-blind, placebo-controlled study ↗
|
|---|
| Blood cholesterol and triglycerides — BC99 | In the full sample, there was no benefit over placebo for total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides. | 2/4 LowOne small study. Body weight and blood lipid measures were additional outcomes. The conclusion applies to all participants combined. A result from one subgroup cannot be generalized to the entire sample. | 11 publication describedEffect of Bacillus coagulans BC99 supplementation on body weight and gut microbiota in overweight and obese individual: a randomized, double-blind, placebo-controlled study ↗ | 66 adults aged 18–65 with overweight or obesity in China, 33 in each group. Each group included 20 participants with overweight and 13 with obesity. | - Effect of Bacillus coagulans BC99 supplementation on body weight and gut microbiota in overweight and obese individual: a randomized, double-blind, placebo-controlled study ↗
|
|---|
| Leg press strength — Unique IS2 with protein and training | The one-repetition maximum on the leg press increased by about 24 kg with the supplement and 14 kg with placebo. These values were estimated from the graph. The abstract reports a between-group p-value of 0.024. | 2/4 LowOne study. Of the 70 assigned participants, 56 completed the protocol. The study assessed the effect alongside whey protein and training. The changes were estimated from a graph in the original article. | 11 publication describedThe effect of Bacillus coagulans Unique IS-2 supplementation on plasma amino acid levels and muscle strength in resistance trained males consuming whey protein: a double-blind, placebo-controlled study ↗ | 70 men with strength-training experience, with an average age of 21, were assigned to two groups of 35. Of these, 56 completed the protocol, 28 in each group. Both groups followed the same strength-training program. | - The effect of Bacillus coagulans Unique IS-2 supplementation on plasma amino acid levels and muscle strength in resistance trained males consuming whey protein: a double-blind, placebo-controlled study ↗
|
|---|
| Vertical jump height — Unique IS2 with protein and training | Vertical jump height increased by about 9 cm with the supplement and 4.5 cm with placebo. These values were estimated from the graph. The abstract reports a between-group p-value of 0.007. | 2/4 LowOne study. Of the 70 assigned participants, 56 completed the protocol. The study assessed the effect alongside whey protein and training. The changes were estimated from a graph in the original article. | 11 publication describedThe effect of Bacillus coagulans Unique IS-2 supplementation on plasma amino acid levels and muscle strength in resistance trained males consuming whey protein: a double-blind, placebo-controlled study ↗ | 70 men with strength-training experience, with an average age of 21, were assigned to two groups of 35. Of these, 56 completed the protocol, 28 in each group. Both groups followed the same strength-training program. | - The effect of Bacillus coagulans Unique IS-2 supplementation on plasma amino acid levels and muscle strength in resistance trained males consuming whey protein: a double-blind, placebo-controlled study ↗
|
|---|
| Skin roughness — SANK70258 | Instrument-measured skin roughness did not improve more than with placebo. The SEr measure changed by +0.26 versus +0.13 on the forehead (p=0.569) and −0.20 versus +0.02 at the outer corners of the eyes (p=0.415). | 2/4 LowOne small study with several skin measures. The analysis included 75 of the 80 women in the study. The women were specifically selected based on skin and bowel characteristics. Individual subgroup findings cannot substitute for the result across all women in the study. | 11 publication describedImprovement of skin condition and intestinal microbiota via Heyndrickxia coagulans SANK70258 intake: A placebo-controlled, randomized, double-blind, parallel-group comparative study ↗ | 80 Japanese women aged 30–65, selected based on self-reported skin roughness, infrequent bowel movements, and gut microbiota measures. The primary analysis included 75 women, 39 on the supplement and 36 on placebo. | - Improvement of skin condition and intestinal microbiota via Heyndrickxia coagulans SANK70258 intake: A placebo-controlled, randomized, double-blind, parallel-group comparative study ↗
|
|---|
| Skin flaking — SANK70258 | Instrument-measured skin flaking did not decrease more than with placebo. The SEsc measure changed by −0.03 versus +0.01 on the forehead (p=0.428) and −0.05 versus −0.02 at the outer corners of the eyes (p=0.605). | 2/4 LowOne small study with several skin measures. The analysis included 75 of the 80 women in the study. The women were specifically selected based on skin and bowel characteristics. Individual subgroup findings cannot substitute for the result across all women in the study. | 11 publication describedImprovement of skin condition and intestinal microbiota via Heyndrickxia coagulans SANK70258 intake: A placebo-controlled, randomized, double-blind, parallel-group comparative study ↗ | 80 Japanese women aged 30–65, selected based on self-reported skin roughness, infrequent bowel movements, and gut microbiota measures. The primary analysis included 75 women, 39 on the supplement and 36 on placebo. | - Improvement of skin condition and intestinal microbiota via Heyndrickxia coagulans SANK70258 intake: A placebo-controlled, randomized, double-blind, parallel-group comparative study ↗
|
|---|
| Water loss through the skin — SANK70258 | Water loss through the skin did not decrease more than with placebo. The change was −0.58 versus −0.53 g/m²·h on the forearm (p=0.880) and +0.60 versus −0.80 g/m²·h at the outer corners of the eyes (p=0.216). | 2/4 LowOne small study with several skin measures. The analysis included 75 of the 80 women in the study. The women were specifically selected based on skin and bowel characteristics. Individual subgroup findings cannot substitute for the result across all women in the study. | 11 publication describedImprovement of skin condition and intestinal microbiota via Heyndrickxia coagulans SANK70258 intake: A placebo-controlled, randomized, double-blind, parallel-group comparative study ↗ | 80 Japanese women aged 30–65, selected based on self-reported skin roughness, infrequent bowel movements, and gut microbiota measures. The primary analysis included 75 women, 39 on the supplement and 36 on placebo. | - Improvement of skin condition and intestinal microbiota via Heyndrickxia coagulans SANK70258 intake: A placebo-controlled, randomized, double-blind, parallel-group comparative study ↗
|
|---|
| Skin lightness — SANK70258 | Instrument-measured skin lightness (L*) increased by 0.55 units with the supplement and decreased by 0.05 units with placebo (p=0.040). Higher values indicate a lighter skin tone. The study did not assess whether the change was visible. | 2/4 LowOne small study with several skin measures. The analysis included 75 of the 80 women in the study. The change in skin lightness was measured with an instrument. The study did not establish how noticeable the change was to the eye. | 11 publication describedImprovement of skin condition and intestinal microbiota via Heyndrickxia coagulans SANK70258 intake: A placebo-controlled, randomized, double-blind, parallel-group comparative study ↗ | 80 Japanese women aged 30–65, selected based on self-reported skin roughness, infrequent bowel movements, and gut microbiota measures. The primary analysis included 75 women, 39 on the supplement and 36 on placebo. | - Improvement of skin condition and intestinal microbiota via Heyndrickxia coagulans SANK70258 intake: A placebo-controlled, randomized, double-blind, parallel-group comparative study ↗
|
|---|